SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-509187"
 

Sökning: id:"swepub:oai:DiVA.org:uu-509187" > Ruxolitinib Prevent...

Ruxolitinib Prevents Ventilator Induced Diaphragm Dysfunction

Addinsall, Alex B. (författare)
Department of Physiology and PharmacologyKarolinska InstituteStockholm
Cacciani, Nicola (författare)
Department of Physiology and PharmacologyKarolinska InstituteStockholm;Department of Clinical NeuroscienceKarolinska InstituteStockholm
Akkad, Hasem (författare)
Department of Physiology and PharmacologyKarolinska InstituteStockholm
visa fler...
Moruzzi, Noah (författare)
Department of Molecular Medicine and SurgeryKarolinska InstituteStockholm
Maestri, Alice (författare)
Department of MedicineKarolinska InstituteStockholm
Shevchenko, Ganna (författare)
Uppsala universitet,Institutionen för kemi - BMC
Bergquist, Jonas (författare)
Uppsala universitet,Analytisk kemi
Ruas, Jorge (författare)
Department of Physiology and PharmacologyKarolinska InstituteStockholm
Larsson, Lars (författare)
Department of Physiology and PharmacologyKarolinska InstituteStockholm;Viron Molecular Medicine InstituteBostonMA
visa färre...
 (creator_code:org_t)
2022-05-13
2022
Engelska.
Ingår i: The FASEB Journal. - : John Wiley & Sons. - 0892-6638 .- 1530-6860. ; 36:S1
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Mechanical ventilation (MV), however brief results in the loss of diaphragm muscle mass and strength, termed ventilator induced diaphragm dysfunction (VIDD). VIDD increases dependence, complicates and prolongs weaning and significantly increases discharge mortality rate and health care costs worldwide. The Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway was recently identified as an important signalling pathway implicated in VIDD, upregulated in the diaphragm following MV and limb muslces during critical care. Regulation of STAT3 is imperritve to skeletal muscle mass and function, as STAT3 is required in proper muscle growth and regeneration, while chronic activation of STAT3 is implicated in muscle dysfunction. As JAK/STAT pathway inhibition can restrict the development of chronic muscle wasting conditons, this study aimed to explore the therapeutic potential of Ruxolitinib, an approved JAK1/2 inhibitor for myelofibrosis, for treatment of CIM. We hypothesised Ruxolitinib would reduce loss of muscle mass and function associated with VIDD. Here, rats were subjected to five days controlled MV (CMV) with and without daily Ruxolitinib gavage. Five-days CMV significantly reduced diaphragm muscle size and impaired specific force, which was associated with 2-fold upregulation of P-STAT3, disrupted mitochondrial structure and respiratory function. Expression of the motor protein myosin was not affected, however CMV may alter myosin function through deamidation post translational modification. Ruxolitinib increases five-day survival rate, restored P-STAT3 expression and preserved diaphragm muscle size and specific force. These functional improvements were associated with improved mitochondrial structure, augmented mitochondrial respiratory function and reversal or augmentation of myosin deamidations. These results provide evidence of the preclinical potential of repurposing Ruxolitinib for the treatment of VIDD.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Fysiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Physiology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy